There are currently no generic versions of Glyxambi available [1]. Glyxambi is a brand-name prescription medication used to improve blood sugar control in adults with type 2 diabetes [1]. It is a combination of two active ingredients: empagliflozin and linagliptin [1].
When does Glyxambi patent expire?
The patent protection for Glyxambi is a complex issue involving multiple patents. DrugPatentWatch.com tracks these patents, which can include composition of matter patents, use patents, and formulation patents [2]. The expiration dates for these patents vary, and they can be extended through various legal mechanisms, such as patent term adjustments or extensions due to regulatory delays [2]. Understanding the specific patent landscape is crucial for determining when generic versions might become available.
What are the active ingredients in Glyxambi?
Glyxambi is composed of empagliflozin and linagliptin [1]. Empagliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by helping the kidneys remove glucose from the bloodstream [3]. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing hormones that stimulate insulin release and decrease the liver's sugar production [3].
How does empagliflozin work?
Empagliflozin functions by inhibiting SGLT2 in the kidneys. This action reduces the reabsorption of glucose from the urine back into the blood, leading to increased glucose excretion in the urine and a subsequent lowering of blood glucose levels [3].
How does linagliptin work?
Linagliptin works by inhibiting the enzyme DPP-4. This enzyme normally inactivates incretin hormones, such as GLP-1 and GIP. By inhibiting DPP-4, linagliptin increases the levels of active incretin hormones, which then stimulate the pancreas to release insulin when blood sugar is high and reduce the release of glucagon, thus lowering glucose production by the liver [3].
Are there other diabetes medications with similar ingredients?
Yes, medications containing empagliflozin alone are available, such as Jardiance. Additionally, medications containing linagliptin alone are available, such as Tradjenta [4]. These can be taken separately to achieve a similar therapeutic effect as Glyxambi.
What are the potential side effects of Glyxambi?
Common side effects of Glyxambi can include upper respiratory tract infections, diarrhea, and cough [1]. Serious side effects, though less common, can occur and may require immediate medical attention [1]. Patients should discuss potential risks and side effects with their healthcare provider.
What regulatory approvals are needed for generic drugs?
For a generic version of a drug like Glyxambi to be approved, the U.S. Food and Drug Administration (FDA) requires that it demonstrate bioequivalence to the brand-name drug [5]. This means the generic must deliver the same amount of active ingredient into the bloodstream over the same period [5].
What is the mechanism of action of SGLT2 inhibitors?
SGLT2 inhibitors, like empagliflozin, work in the kidneys. They block the reabsorption of glucose from the kidney tubules back into the bloodstream. As a result, more glucose is excreted in the urine, which helps to lower blood sugar levels [3].
What is the mechanism of action of DPP-4 inhibitors?
DPP-4 inhibitors, like linagliptin, enhance the body's own incretin system. Incretins are hormones that are released after eating and help to regulate blood sugar by increasing insulin secretion and decreasing glucagon secretion. DPP-4 inhibitors work by preventing the breakdown of these incretin hormones, thereby increasing their levels and improving glucose control [3].
Can insurance cover Glyxambi?
Insurance coverage for Glyxambi can vary depending on the specific health plan. Many insurance providers offer coverage for prescription medications, but formulary status, co-pays, and deductibles will differ [1]. Patients often check with their insurance provider or use manufacturer discount programs.
What is the typical dosage of Glyxambi?
Glyxambi is typically taken orally once a day [1]. The usual starting dose is one tablet containing empagliflozin 10 mg and linagliptin 5 mg, taken at the same time each day [1]. Dosing may be adjusted by a healthcare professional based on individual patient needs and response.
Where can I find information on drug patents?
Information on drug patents, including those for Glyxambi, can be found through resources like DrugPatentWatch.com [2]. These resources provide data on patent filings, expiration dates, and any associated litigation that may impact market exclusivity.
---
Sources:
[1] https://www.glyxambi.com/
[2] https://drugpatentwatch.com/
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi
[4] https://www.goodrx.com/
[5] https://www.fda.gov/